Keith is a seasoned biopharma executive, serving as Chairman, CEO, and Board Member for multiple companies. He specializes in late-stage drug development, FDA approvals, and strategic exits, notably leading Avanir Pharmaceuticals to a $3. 5 billion acquisition. Keith holds an MBA from UCLA Anderson and a BS from Indiana University, and is a licensed Certified Public Accountant.
While his professional life is demanding, Keith maintains a connection to his academic roots, showing interest in his alma maters, Indiana University and the UCLA Anderson School of Management. This suggests an appreciation for the foundational role these institutions played in his successful career in the biopharmaceutical industry.
He co-founded Ambros Therapeutics to address a critical unmet need, stating, "There are no medicines approved for CRPS-1 patients in the U. S. "
Keith Katkin
Chairman and Co-Founder at Ambros Therapeutics
Aliso Viejo, California, United States
Overview
Topics They Care About
Strategic Biopharma Exits
He has a strong track record of leading biopharmaceutical companies to successful acquisitions, including the $3. 5 billion sale of Avanir Pharmaceuticals to Otsuka.
Late-Stage Drug Development
His career focuses on navigating companies through pivotal trials and the FDA approval process, bringing new therapies to market for underserved patient populations.
Rare Disease Treatment
As Co-Founder of Ambros Therapeutics, he is currently focused on developing a first-in-class medicine for Complex Regional Pain Syndrome type 1 (CRPS-1).
Media Appearances
Ambros Therapeutics Launches with $125 Million Series A Financing to Advance Neridronate Through Phase‑3 Registrational Program for Complex Regional Pain Syndrome Type‑1. Featured in PR Newswire
Abiogen Pharma participates in the birth of Ambros Therapeutics. Featured in Il Sole 24 Ore
Work History
2024
Chairman and Co-Founder at Ambros Therapeutics
4-2022
Board Member at Emergent BioSolutions
2020 - 2024
Adviser to the Board of Directors at Urovant Sciences, Inc.
9-2017 - 4-2020
President and CEO at Urovant Sciences
2017
Board Member at Syndax Pharmaceuticals
9-2015 - 4-2017
Board Member at CoverMyMeds
2015
Chairman of the Board of Directors at Eledon Pharmaceuticals, Inc.
2015 - 2022
Board Member at Rigel Pharmaceuticals Inc.
12-2014 - 11-2016
Board Member at Carbylan Therapeutics
2007 - 2016
CEO at Avanir Pharmaceuticals
2007 - 2016
Board Member at Avanir Pharmaceuticals
2005 - 2007
Sr.Vice President, Sales and Marketing at Avanir Pharmaceuticals
2003 - 2005
Vice President, Commercial Development at Peninsula Pharmaceuticals
2002 - 2003
Vice President, Marketing at InterMune
1996 - 2002
Sales and Marketing at Amgen
1993 - 1996
Finance, Business Development and Commercial at Abbott Laboratories
Education
1997 - 2000
MBA from UCLA Anderson School of Management
1989 - 1993
BS from Indiana University Bloomington
More Information
Social Presence :
Prographics :
Exp : 33
Location : Aliso Viejo, California, United States
Job Level : Leadership
Designation : Chairman and Co-Founder at Ambros Therapeutics
